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Abstract 
Aim: The present study aimed to assess the predicting factors contributing to ineffective 
drainage in the first transpapillary uncovered self-expandable metal stents (USEMS) 
placement for cases of unresectable malignant hilar biliary obstruction (UMHBO) with 
Bismuth type II or higher.  
Methods: This was a retrospective, single-center study. A total of 97 cases of UMHBO 
patients that underwent technically successful first USEMS placement using endoscopic 
retrograde cholangiopancreatography (ERCP) were divided to 73 of effective drainage group 
and 24 of the ineffective drainage group. The characteristics, clinical outcomes and drained 
liver volume were compared. Drained liver volume was measured by using computed 
tomography volumetry. The definition of effective biliary drainage was a 50% decrease in the 
serum total bilirubin level or normalization of the level within 14 days of stent placement. 
Results: Univariate analysis showed that a high pre-ERCP serum T.Bil level (P = 0.0075), 
low pre-ERCP albumin level (P = 0.042), presence of cirrhosis (P = 0.010), drainaed liver 
volume (P = 0.0010), and single stenting (P = 0.022) were significantly contributed to 
ineffective drainage. Multivariate analysis showed that presence of cirrhosis (adjusted odds 
ratio = 5.79; 95% confidence interval = 1.30, 25.85; P = 0.022) and drained liver volume 
<50% (adjusted odds ratio = 5.50; 95% confidence interval = 1.50, 20.25; P = 0.010) were 
independent risk factors for ineffective drainage. 
Conclusion: The significant factors contributing to ineffective drainage in the first 
transpapillary USEMS placement for UMHBO were comorbid of cirrhosis and drainaed liver 
volume < 50%. 
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Malignant hilar biliary obstruction (MHBO) is caused by cholangiocarcinoma, gallbladder 
carcinoma, metastatic liver tumors, or hilar lymph node metastases of various cancers. And 
effective drainage of obstructive jaundice is essential for starting chemotherapy or improving 
the quality of life of patients. Previous studies have compared the use of plastic stents and 
metal stents (MS) in patients with unresectable MHBO (UMHBO) and have reported that MS 
were superior in terms of patency period and cost effectiveness 1,2. Moreover, uncovered self-
expandable MS (USEMS) are now mainly used for the drainage of UMHBO. Metal stenting 
methods are diversifying, which include side-by-side placement (SBS), partial stent-in-stent 
placement (PSIS), and single stenting (Fig.1). However, with regard to the drained liver 
volume and stenting method for UMHBO using MS, there are no unified guidelines 3. 
Furthermore, the predicting factors contributing to ineffective drainage in the first 
transpapillary USEMS placement for cases of UMHBO are unclear. In TOKYO Criteria 2014 
4, functional success, which indicates effective biliary drainage, was defined as a 50% 
decrease in the serum T.Bil level or normalization of the serum T.Bil level within 14 days of 
stent placement. The present study aimed to assess the predicting factors contributing to 
ineffective drainage in the first transpapillary USEMS placement for cases of UMHBO with 
Bismuth type II or higher.  
 
Materials and Methods 
Study design  
This was a retrospective, single-center study. We reviewed the medical records of patients 
and compared their characteristics and clinical outcomes between those with ineffective 
drainage and those with effective drainage after USEMS placement for UMHBO. And, we 
also measured the drained liver volume by using computed tomography (CT) volumetry, then 
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we compared them between the two groups. This study was approved by the ethics 
committee of Chiba University Hospital. 
 
Patients 
Inclusion criterion for this study was patients with UMHBO who underwent technically 
successful first endoscopic SEMS placement for biliary drainage at Chiba University 
Hospital between July 2005 and September 2017. Technical success was defined as SEMS 
placement with sufﬁcient coverage of the bile duct stricture. Exclusion criteria were as 
follows: cases with percutaneous transhepatic biliary drainage; cases of Bismuth type I; cases 
with percutaneous transhepatic stenting in combination; cases with biliary tract 
reconstruction; cases without abdominal CT scan within 14 days before stenting; or cases 
with ambiguous stenting information. 
 
Techniques  
Transpapillary SEMS placement for biliary drainage was performed by therapeutic 
duodenoscopy (JF 260 V or TJF 260 V, Olympus, Tokyo, Japan) using endoscopic retrograde 
cholangiopancreatography (ERCP). SEMSs included the Zilver635 biliary stent (Cook Japan, 
Tokyo, Japan), X-Suit NIR (Olympus, Tokyo, Japan), WallFlex (Boston Scientific Japan, 
Tokyo, Japan), Niti-S D-type (Century Medical, Tokyo, Japan), BILERUSH (PIOLAX, 
Yokohama, Japan), and JOSTENT (Zeon Medical, Tokyo, Japan). In SBS and PSIS, which 
are required to place stents into two bile ducts, stent placements were completed with one-
time ERCP in all cases. Stenting in two bile ducts with SBS and PSIS together was referred 
to as multiple stenting in this study. Additionally, stent placement in one branch of the bile 
duct was referred to as single stenting in this study.  
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Methods 
In this study, cases satisfying the functional success criteria of the TOKYO Criteria 2014 
without additional interventions were included in the effective drainage group, and the 
remaining cases were included in the ineffective drainage group. Functional success was 
defined as a decrease in the serum T.Bil level to < 50% or < 2.0 mg/dl within 14 days of 
SEMS placement without additional biliary treatment. The characteristics, clinical outcomes 
and drained liver volume were compared between the groups. The following variables of the 
effective drainage group and ineffective drainage group were considered: age, sex, the 
Eastern Cooperative Oncology Group performance status, indications, Bismuth types 5, 
stenting method, complications, pre-ERCP serum T.Bil level, pre-ERCP serum albumin 
level, comorbid cholangitis, comorbid cirrhosis, and drained liver volume. Bismuth types 
were judged based on the findings of retrograde cholangiography and CT findings. 
Complications were evaluated according to the TOKYO Criteria 2014. Liver cirrhosis was 
diagnosed by two gastroenterologists as follows. We diagnosed liver cirrhosis as patients 
with medical history and laboratory data suggestive of cirrhosis, and image findings 
characteristic of liver cirrhosis on abdominal ultrasound, CT, or magnetic resonance imaging.  
As for measurement of drained liver volume using CT volumetry, previous reports 6,7 were 
referred and consultation was done with two radiologists and two gastroenterologists, and an 
assessment method was decided as follows. According to the distribution of the portal vein 
branches, the 4 sectors of the liver were defined: lateral and medial sectors of the left liver, 
and anterior and posterior sectors of the right liver, excluding caudate lobe (Fig.2). The area 
of each sector was calculated by manual tracing using CT scans (axial image) with a 5 mm 
slice thickness, and the volume of sectors were calculated as the summed area of slices 
comprising each sector. Then, the drained liver volume was calculated based on stent 
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position, the non-tumor volume of each liver sector, and the type of bile duct stricture 
according to the Bismuth classification. 
 
Statistical analysis 
Univariate analysis was performed for comparisons between the effective drainage group 
and ineffective drainage group, and Pearson’s chi-square test and Mann-Whitney U test were 
used to assess differences in demographic and clinical variables. For multivariate analysis, 
binomial logistic regression analysis was performed on items that were significant in 
univariate analysis. Additionally, for continuous variables, classification was performed using 
cutoff values calculated by determining the smallest distance between the receiver operating 
characteristic (ROC) curve and the upper left corner of the graph, and multivariate analysis 
was performed. Data are presented as median [interquartile range (IQR)] or number (%). A P-
value < 0.05 was considered statistically significant. All statistical analyses were conducted 
using BellCurve for Excel (Social Survey Research Information Co., Ltd., Tokyo, Japan). 
 
Results 
A total of 119 cases fulfilled the inclusion criteria. However, 22 case was excluded (Fig.3). 
Therefore, 97 cases were eligible. The characteristics and treatment outcomes are shown in 
Table 1. There were 67 male and 30 female patients [median (IQR), 69 (63–78)]. Of the 97 
cases, 34 involved SBS, 18 involved PSIS, and 45 involved single stenting. Even SBS and 
PSIS, there were no cases in which stents were placed in three or more branches of bile duct. 
Endoscopic sphincterotomy was performed in all cases before SEMS placement. There were 
no cases with marked thrombocytopenia, and there were no cases of dialysis.  
Of the 97 eligible cases, 73 were included in the effective drainage group and 24 were 
included in the ineffective drainage group (Table 2). Univariate analysis showed that pre-
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ERCP serum T.Bil level (P = 0.0075), pre-ERCP albumin level (P = 0.042), comorbid of 
cirrhosis (P = 0.010), drainage liver volume (P = 0.0010), and single stenting (P = 0.022) 
were significant factors contributed to ineffective drainage. 
The areas under the ROC curve for pre-ERCP serum T.Bil, pre-ERCP serum albumin levels, 
and drained liver volume were 0.683, 0.639, and 0.724, respectively. The cutoff values for 
pre-ERCP serum T.Bil, pre-ERCP serum albumin levels, and drained liver volume were 4.8 
mg/dl (sensitivity, 75%; specificity, 68%) and 2.6 mg/dl (sensitivity, 50%; specificity, 81%), 
and 50% (sensitivity, 75%; specificity, 74%), respectively. Pre-ERCP serum T.Bil, pre-ERCP 
serum albumin levels, and drained liver volume were classified using the cutoff values, and 
multivariate analysis was performed. 
Multivariate analysis was performed using the five items that were significant factors in 
univariate analysis (Table 3). The multivariate analysis showed that presence of cirrhosis 
(adjusted odds ratio = 5.79; 95% confidence interval = 1.30, 25.85; P = 0.022) and drained 
liver volume <50% (adjusted odds ratio = 5.50; 95% confidence interval = 1.50, 20.25; P = 
0.010) were independent risk factors for ineffective drainage.  
 Complications occurred in 10 cases (10%). With regard to the type of complications, there 
were five cases of cholangitis, two cases of pancreatitis, and one case of hepatic abscess, 
pneumonia, and heart failure each. For the case of hepatic abscess, the abscess formed in a 
non-drainage area and additional stent placement was required. Other complication cases 
were quickly relieved. And there was no death associated with SEMS placement. 
Discussion 
This study aimed to assess the risk factors contributing to ineffective drainage in the first 
transpapillary USEMS placement for cases of UMHBO with Bismuth type II or higher. The 
statistically significant risk factors contributing to ineffective drainage were found to be 
presence of cirrhosis and drained liver volume < 50%.  
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In the early part of the first decade of the 2000s, some reports mentioned that single stenting 
was sufficient for bilirubin decrease 8,9. A prospective study with 35 patients showed that 
unilateral metal stenting using magnetic resonance cholangiopancreatography or CT to 
selectively target drainage provided safe and effective palliation in most patients with MHBO 
8. A prospective study with 61 patients showed that unilateral MS placement was safe and 
feasible and achieved adequate drainage in majority of the patients with unresectable hilar 
cholangiocarcinoma 9. However, in recent years, many studies have been reported on the 
efficacy of multiple stenting 10-15. However, there are few reports on factors contributing to 
ineffective drainage, and these factors were not clear. Drained liver volume is considered to 
be important for effective drainage 6,7, the following two reports evaluated the drainage liver 
volumes using CT volumetry. Vennie et al 6 reported drainage of > 50% of the variable liver 
volume was an important predictor of drainage and to provide effective palliation for 
MHBSO patients. Takahashi et al 7 reported liver volume drainage ≥ 33% in patients with 
preserved liver function correlated with effective biliary drainage in UMHBO. Both studies 
had employed various biliary drainage methods. But our study analyzed only the first 
USEMS placement cases with UMHBO.  This study is the first report to investigate what 
kind of factor contributes to ineffective drainage in initial metal stenting for UMHBO.  
As for the strategy in the first transpapillary USEMS placement for cases of UMHBO with 
Bismuth type II or higher, stenting method draining ≥ 50% of liver volume should be 
planned. Particularly in Bismuth type IV, multiple stenting is necessary to raining ≥ 50% of 
liver volume, and multiple stenting should adapt positively. Liver volume and drainage 
region can be easily assessed using a CT scan without requiring special software; therefore, it 
is considered to be a useful method. A prospective study would be helpful in validating 
results of this study. It should also be noted that in cases of cirrhosis, it is difficult to obtain 
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effective drainage. The number of cases of cirrhosis was small in our study, and further study 
is necessary to assess the condition necessary for effective drainage in cirrhosis cases. 
The present study had several limitations. First, this was a retrospective study at a single 
center. The stenting procedures were not uniform, and there were cases in which stents could 
not be inserted in the intended place. Additionally, the number of cases was limited. Second, 
the history of biliary drainage differed from case to case, and it affected pre-ERCP T.Bil. 
Third, there were many types of disease; this was a study targeting heterogeneous population. 
Finally, the method of CT volumetry may have room for improvement.  
Conclusion 
The significant factors contributing to ineffective drainage in the first transpapillary USEMS 
placement for UMHBO were the presence of cirrhosis and drained liver volume <50%. The 
strategy in the first transpapillary USEMS placement for cases of UMHBO with Bismuth 
type II or higher, stenting method draining ≥50% of liver volume should be planned. 
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Figure legends 
Fig. 1. Placement methods of biliary metal stents 
a: Side-by-side placement  
b: Partial stent-in-stent placement  
c: Single stenting 
Fig. 2. Identification of liver sections in computed tomography volumetry. According to the 
distribution of portal vein branches, the 4 sectors of the liver were defined as follows: lateral 
(a) and medial (b) sectors of the left liver, and anterior (c) and posterior (d) sectors of the 
right liver, excluding caudate lobe. 
Fig. 3. Diagram of case selection flow  
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Table 1. Clinical features of 97 cases  
Characteristics and clinical outcomes   
Age, median(IQR) 69 (63-78) 
Sex, male(%) 67 (69%) 
Performance status, median(IQR) 1 (1-3) 
Indications, n(%)  
Cholangiocarcinoma 54 (56%) 
Gallbladder carcinoma 17 (18%) 
Hepatocellular carcinoma 14 (14%) 
Metastatic liver tumor 10 (10%) 
Hilar lymph nodes metastasis 2 (2%) 
No previous biliary drainage, n(%) 23 (24%) 
Pre-ERCP serum T.Bil in mg/dl, median(IQR) 4.8 (1.7-9.8) 
Pre-ERCP serum albumin in mg/dl, median(IQR) 2.9 (2.6-3.3) 
Comorbid of cholangitis, n(%) 18 (19%) 
Comorbid of cirrhosis, n(%) 16 (16%) 
Bismuth classification type, n(%)   
Type II 12 (12%) 
Type III 20 (21%) 
Type IV 65 (67%) 
Stenting method, n(%)  
Side-by-side placement 34 (35%) 
Partial stent-in-stent placement 18 (19%) 
Single stenting 45 (46%) 
Stent placement above the papilla, n(%) 90 (93%) 
Drained liver volume in %, median(IQR) 53.5 (42.3-61.8) 
Effective drainage, n(%) 73 (75%) 
Complication, n(%) 10 (10%) 
IQR, interquartile range; ERCP, endoscopic retrograde cholangiopancreatography;  
T.Bil, total bilirubin  
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Table 2. Univariate analysis for risk factors of ineffective biliary drainage 
  Effective drainage Ineffective drainage 
P value 
  n=73  n=24 
Age, median(IQR) 71 (64-79) 67 (61-71) 0.056 
Sex, male(%) 49 (67%) 18 (75%) 0.47 
Performance status, median(IQR) 1 (1-3) 1 (1-2) 0.27 
Cholangiocarcinoma, n(%) 44 (60%) 10 (42%) 0.11 
Gallbladder carcinoma, n(%) 12 (16%) 5 (21%) 0.62 
Hepatocellular carcinoma, n(%) 10 (14%) 4 (17%) 0.72 
Metastatic liver tumor, n(%) 6 (8%) 4 (17%) 0.24  
Hilar lymph nodes metastasis, n(%) 1 (1%) 1 (4%) 0.40  
No previous biliary drainage, n(%) 15 (21%) 8 (33%) 0.20  
Pre-ERCP serum T.Bil in mg/dl, median(IQR) 3.9 (1.5-7.7) 8.2 (4.6-13.9) 0.0075 
Pre-ERCP serum albumin in mg/dl, median(IQR) 2.9 (2.7-3.3) 2.7 (2.1-3.2) 0.042 
Comorbid of cholangitis, n(%) 11 (15%) 7 (29%) 0.12 
Comorbid of cirrhosis, n(%) 8 (11%) 8 (33%) 0.010  
Bismuth classification type , n(%)    
Type II 10 (14%) 2 (8%) 0.49 
Type III 14 (19%) 6 (25%) 0.54 
Type IV 49 (67%) 16 (67%) 0.97 
Drained liver volume in %, median(IQR) 56 (49-64) 40 (34-51) 0.001 
Side-by-side placement, n(%) 29 (40%) 5 (21%) 0.092 
Partial stent-in-stent placement, n(%) 15 (21%) 3 (13%) 0.38 
Single stenting, n(%) 29 (40%) 16 (67%) 0.022 
Stent placement above the papilla, n(%) 67 (92%) 23 (96%) 0.51 
IQR, interquartile range; ERCP, endoscopic retrograde cholangiopancreatography; T.Bil, total bilirubin 
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Table 3. Multivariate analysis for risk factors of ineffective biliary drainage   
  
Adjusted odds ratio 
95% Confidence 
interval P value 
  Lower Upper 
Pre-ERCP serum T.Bil ≥ 4.8 mg/dl 3.45  0.96  12.42  0.058  
Pre-ERCP serum albumin ≤ 2.6 mg/dl 3.15  0.88  11.29  0.077  
Single stenting 1.42  0.36  5.55  0.620  
Drainage liver volume < 50% 5.50  1.50  20.25  0.010  
Comorbid of cirrhosis 5.79  1.30  25.85  0.022  
ERCP, endoscopic retrograde cholangiopancreatography; T.Bil, total bilirubin  
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